特徴
- Saroglitazar is a drug for the treatment of type 2 diabetes mellitus and dyslipidemia. It is approved for use in India by the Drug Controller General of India. Saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a characteristic hallmark of atherogenic diabetic dyslipidemia (ADD). Saroglitazar is novel first in class drug which acts as a dual PPAR agonist at the subtypes α (alpha) and γ (gamma) of the peroxisome proliferator-activated receptor (PPAR). Agonist action at PPARα lowers high blood triglycerides, and agonist action on PPARγ improves insulin resistance and consequently lowers blood sugar.
- Synonyms:(αS)-α-Ethoxy-4-[2-[2-methyl-5-[4-(methylthio)phenyl]-1H-pyrrol-1-yl]ethoxy]benzenepropanoic Acid; ZYH1; ZYH-1; ZYH 1; Lipaglyn
- IUPAC/Chemical Name: (S)-2-ethoxy-3-(4-(2-(2-methyl-5-(4-(methylthio)phenyl)-1H-pyrrol-1-yl)ethoxy)phenyl)propanoic acid
- Molecular Formula:C₂₅H₂₉NO₄S
- Molecular Weight:439.57
- Appearance:Red gel
- Purity:As reported
- Solubility:Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
- Storage and Stability:Store at 4°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
仕様
- Size:25mg
- Source Antigen:Synthetic
- Grade:Highly Purified
- Purity:As reported
- Form:Red gel
- Molecular Formula:C₂₅H₂₉NO₄S
- Molecular Weight Non Ab:439.57
- EU Commodity Code:38220090
- この商品は法規制を確認しておりません。(法規制によって販売できない場合もございます)
- 製品の仕様は予告なく変更になる場合がございます。最新仕様はメーカーホームページをご確認ください。
- 【試薬に関するお問合せ】
- アズワン株式会社 試薬・プロセス材料グループ
- TEL:06-6447-8641
- FAX:06-6447-8642
- E-mail:[email protected]
よくあるご質問(FAQ)
掲載カタログ情報
| 掲載カタログ名 | 掲載ページ |
|---|





